

CIF A-18.758.300
Avda. de la Innovación, n 1
Edificio BIC (Ofic. 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 Madrid

In Granada, 21 January 2015

RELEVANT FACT OF NEURON BIO

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB, the company Neuron Bio, S.A. (hereinafter "NEURON BIO" or the "Company"), hereby informs about the following. At its meeting of 20 January 2015 the Board of Directors agreed:

1. In accordance to the delegation conferred in the General Shareholders' Meeting held on 25 July 2014, to increase the share capital of the Company by issuing up to 1,387,500 new shares, which may be all of the same class and series as those currently outstanding and represented through book-entries. The new shares will be issued at 1.40 EURO per each new share thus with an issue premium of 0.40 EURO. Proportion will be of one new share for every 5 current shares, recognizing pre-emptive subscription rights of the shareholders.

The increase will begin once the legal procedures of the MAB have been complied.

2. Call for an Extraordinary Shareholders Meeting, after having obtained the appropriate mandatory reports from an independent expert in order to inform and submit for approval by shareholders the following:

The new strategic plans from NEURON BIO and Neol, which will be presented at the meeting, the necessary financial instruments to implement these plans, the delivery to Neuron shareholders of a relevant percentage of the share capital from Neol Biosolutions free of charge and its subsequent flotation into the MAB (alternative stock market).

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors